Literature DB >> 29794391

Importance of Early Diagnosis of Cardiac Sarcoidosis in Patients with Complete Atrioventricular Block.

Toyoji Kaida1, Takayuki Inomata2, Yoshiyasu Minami1, Mayu Yazaki1, Teppei Fujita1, Yuichiro Iida1, Yuki Ikeda1, Takeru Nabeta1, Shunsuke Ishii1, Takashi Naruke1, Emi Maekawa1, Toshimi Koitabashi1, Junya Ako1.   

Abstract

Our aim is to clarify the factors for early diagnosis of cardiac sarcoidosis (CS) in patients with complete atrioventricular block (CAVB) and its impact on cardiac function after corticosteroid therapy.A total of 15 CS patients with CAVB who underwent corticosteroid therapy were retrospectively analyzed. Patients were divided into two groups according to the time from the first CAVB onset to the diagnosis of CS. Clinical characteristics and outcomes were compared between the early diagnosis group (within 1 year; group E, n = 10) and the late diagnosis group (over 1 year; group L, n = 5).The history of extracardiac sarcoidosis (60 versus 0%, P = 0.0440) and abnormal findings on echocardiography (70 versus 0%, P = 0.0256) at the CAVB onset were significantly more frequent in group E than in group L. The change of left ventricular ejection fraction (LVEF) and brain natriuretic peptide (BNP) levels was significantly better in group E than in group L (0.8 ± 2.8 versus -32.4 ± 3.9%, P < 0.0001; -11.1 ± 16.0 versus 161.8 ± 35.8 pg/mL, P = 0.0013, respectively). After corticosteroid therapy, the LVEF and BNP levels were also significantly better in group E than in group L (53.3 ± 10.7 versus 37.0 ± 9.3%, P = 0.0128; 63.0 ± 46.4 versus 458.8 ± 352.0 pg/mL, P = 0.0027).The diagnosis may be delayed in CS patients with CAVB without history of extracardiac sarcoidosis. Abnormal findings on echocardiography contributed to the early diagnosis of CS. Therefore, the diagnosis of CS may be missed or delayed in patients without them. Time delay from the CAVB onset to the CS diagnosis may exacerbate the cardiac function.

Entities:  

Keywords:  Corticosteroid therapy; Echocardiography

Mesh:

Substances:

Year:  2018        PMID: 29794391     DOI: 10.1536/ihj.17-492

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  5 in total

1.  Controversies in the Treatment of Cardiac Sarcoidosis.

Authors:  Ogugua Ndili Obi; Elyse E Lower; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

2.  Clinical valuables related to resolution of complete or advanced atrioventricular block after steroid therapy in patients with cardiac sarcoidosis.

Authors:  Takeru Nabeta; Masahiko Hara; Takashi Naruke; Kenji Maemura; Takumi Oki; Mayu Yazaki; Teppei Fujita; Yuki Ikeda; Shunsuke Ishii; Toshimi Koitabashi; Junya Ako
Journal:  J Arrhythm       Date:  2021-06-24

Review 3.  Hit-hard and early versus step-up treatment in severe sarcoidosis.

Authors:  Adriane D M Vorselaars; Daniel A Culver
Journal:  Curr Opin Pulm Med       Date:  2022-07-23       Impact factor: 2.868

4.  The harm of delayed diagnosis of arrhythmogenic cardiac sarcoidosis: a case series.

Authors:  Jarieke C Hoogendoorn; Maarten K Ninaber; Sebastiaan R D Piers; Marta de Riva; Robert W Grauss; Frank M Bogun; Katja Zeppenfeld
Journal:  Europace       Date:  2020-09-01       Impact factor: 5.214

5.  Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review.

Authors:  Siavosh Fazelpour; Mouhannad M Sadek; Pablo B Nery; Rob S Beanlands; Niko Tzemos; Mustafa Toma; David H Birnie
Journal:  J Am Heart Assoc       Date:  2021-09-02       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.